The impact of GLP-1 medications on the gut microbiota, which is partly mediated by gut IELs, may also affect the intestinal response to inflammation and its interaction with the host immune system, warranting further investigation
Despite the absence of improvement in the primary endpoint, noteworthy findings were reported, including a significant reduction in manifestations such as bloating, nausea, postprandial fullness, and bellyache
Recent research suggests that without lifestyle support, such as strength training and adequate protein intake, patients on GLP-1s can lose up to 40 percent of their total body weight, primarily from lean muscle mass rather than fat
NAION comes on suddenly and cannot be reversed, and people who take Wegovy and other GLP-1s are developing it at a higher rate than the general public